Effect of Early Administration of TXA in Adult Hip Fractures

Conditions

• Postoperative Blood Loss

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Tranexamic acid — DRUG
  TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups

Study Details

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Key Dates

Start date

Sep 1, 2021

Status verified

Sep 2021

Primary completion

Jul 1, 2022

Completion

Jul 1, 2022

Study Design

Enrollment

170 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: Early Adminstration of TXA + Intraoperative TXA
  This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
• Other: Intraoperative only TXA
  This group will only receive the intraoperative TXA.

Primary Outcome Measure

Postoperative Blood Transfusion [ Time Frame: Up to two weeks ]

Central Contacts

• Jacob Hinkley, DO, MS
  810-606-5669
  [email protected]
• Jacob Lytle, DO
  810-606-5669
  [email protected]

Locations (1)

Find similar trials in Grand Blanc, MI

Related Studies

• Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis
  PHASE1 · Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee